Sidley represented Ferring Pharmaceuticals (China) Co., Ltd. (“Ferring Pharmaceuticals”) in its strategic collaboration with Hybio Pharmaceutical Co., Ltd. (“Hybio Pharmaceutical”) where the Marketing Authorization of Cetrotide (cetroelix acetate for injection) in Mainland China will be transferred to Ferring Pharmaceuticals; and Hybio Pharmaceutical will act as the contract manufacturing organization of Ferring Pharmaceuticals.
Headquartered in St. Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group as well as a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.
The Sidley team was led by senior counsel Chen Yang and counsel Jing Lu.
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.